Islamabad, Oct 22: China-Pakistan Strategic Partnership Signed to Promote CAR-T Therapy Development in Pakistan. Last week, Beijing Yuanxin Huibao Technology Co.Ltd. the Pakistan China Business Association, and Nanjing IASO Biotechnology Co.Ltd. signed a strategic cooperation agreement in Beijing with the goal of advancing the availability of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy (henceforth referred to as CAR-T Therapy) for adult patients with multiple myeloma in Pakistan.
The partnership will not only bring cutting-edge CAR-T Therapy to Pakistani patients, but it will also introduce novel payment models to reduce financial burdens and improve drug accessibility, according to Tahir Farooq, President of the China-Pakistan Business Association, who spoke at the signing ceremony, China Economic Net (CEN) reported on Tuesday.
IASO Biotechnology’s head of overseas operations, Eric Tian, offered insights on how this strategic partnership will capitalize on each partner’s unique strengths to promote the creation of novel treatment approaches, ultimately resulting in more effective CAR-T treatments for patients in Pakistan.
One of the most promising developments in cell therapy is CAR-T therapy, especially for the treatment of hematological malignancies. According to Peng Xuan, CEO of Yuanxin Huibao, this partnership would greatly increase the accessibility of CAR-T treatments, allowing more patients in Pakistan to take advantage of this innovative treatment.
